Paris – 28.05.2026: In an important development for obesity treatment in France, Health Minister Stéphanie Rist announced today that the drugs Wegovy and Mounjaro will now be reimbursed. This decision marks a significant step in the fight against obesity, which affects more than eight million people in France.
Wegovy, a drug from Danish pharmaceutical group Novo Nordisk, had not been reimbursed in France since its introduction in October 2024 and cost patients between €274 and €365 per month. With the new reimbursement policy, the price for the first three doses is set at €146.91 per month, representing a considerable saving for patients.
The decision to reimburse Wegovy and Mounjaro was made after intense negotiations between the French Ministry of Health and the manufacturers. These discussions focused on defining a fair price and determining the reimbursement share by public health insurance. Although the exact details of the agreement have not yet been published, reimbursement is expected to take effect in the second half of 2026.
The reimbursement of these drugs is expected to have a significant impact on obesity treatment in France. Experts estimate that the annual costs for reimbursement will be around €100 million. This investment is considered necessary to address the rising healthcare costs related to obesity and to improve the quality of life of affected patients.
Nuevo Nordisk welcomed the French government’s decision, emphasizing that reimbursing Wegovy represents an important advance in the fight against obesity. The company also announced that it would reduce the price of Wegovy in France to €146.91 per month for the first three doses to further increase the drug’s accessibility.
The introduction of reimbursement for Wegovy and Mounjaro is seen by health experts as a step in the right direction to improve obesity treatment in France. However, it is emphasized that a comprehensive strategy is needed that, in addition to pharmacological therapies, includes preventive measures and an improvement in the population’s eating habits.
The French government plans to widely inform the public in the coming weeks about the details of the reimbursement and the conditions for prescribing Wegovy and Mounjaro. Patients interested in treatment with these drugs should consult their general practitioner or a specialist for further information and to discuss the most suitable therapeutic option for them.
The decision to reimburse Wegovy and Mounjaro in France is considered a significant step in the fight against obesity and could serve as a model for other European countries facing similar challenges. It remains to be seen how this decision will affect the prevalence of obesity and related healthcare costs in France.